AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Male Sexual Health Questionnaire (MSHQ)
Description: Male Sexual Health Questionnaire (MSHQ) assessment in patients with past SARS-CoV 2 infection
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: IPSS questionnaire
Description: IPSS assessment in patients with past SARS-CoV 2 infection
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SECRET questionnaire
Description: SECRET questionnaire assessment in patients with past SARS-CoV 2 infection
Study NCT04446169 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Interleukin assessment in semen
Description: Assessment of Interleukin presence and quantitative analysis in semen, to study if a previous inflammation/infection due to SARS-CoV 2 in testis was present
Study NCT02917083 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CAR T Cells
Description: Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three to six patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:~Dose Level One: 2x10\^7 cells/m2. Dose Level Two: 1x10\^8 cells/m2. Dose Level Three: 2x10\^8 cells/m2.
Study NCT03265262 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: The basophil activation test (BAT)
Description: Single sample: 5 mL of venous blood
Study NCT01554462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid / Docosahexaenoic acid
Description: 650 mg EPA + 650 mg DHA daily
Study NCT01554462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dietary intervention (MUFA) in ADHD group
Description: Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
Study NCT01615731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400mcg buccal misoprostol 90 minutes pre-op
Study NCT01615731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op
Study NCT01615731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-amniotic digoxin
Description: 1mg digoxin administered intra-amniotically \~24 hours pre-op
Study NCT01772433 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive oil
Description: Phonophoresis with Olive oil for 10 day, daily
Study NCT01772433 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phonophoresis gel
Description: Phonophoresis with base gel for 10 days, daily
Study NCT04543123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS treatment
Description: Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
Study NCT04543123 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS treatment
Description: Participants visited the hospital four times (biweekly for two weeks). During their second visit, a research nurse instructed each participant on use of home-based tDCS equipment (YDS-301N; Ybrain Inc., Seongnam-si, Korea) and all participants thereafter conducted tDCS treatment at home once a day for 30 minutes (five times per week).
Study NCT04543123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Drug(escitalopram)
Description: Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
Study NCT04543123 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Antidepressant Drug(escitalopram)
Description: Participants in both active and sham groups were prescribed escitalopram in combination with tDCS treatment.
Study NCT03998423 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Double-encapsulated Fecal Microbiota Transplant Capsules
Study NCT02658643 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous suture technique
Description: The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
Study NCT03282877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCST web-application
Description: The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
Study NCT02658643 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture technique
Description: The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
Study NCT00672048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computer Tablet
Description: A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
Study NCT00672048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuing Education Course
Description: Annual standard continuing education
Study NCT04405206 — intervention group
Intervention type: PROCEDURE
Intervention: Nonoperative Management
Description: Watch and Wait
Study NCT04405206 — intervention group
Intervention type: PROCEDURE
Intervention: Local excision
Description: For ymriT1N0 and near-cCR patients，LE is optional.
Study NCT04405206 — intervention group
Intervention type: PROCEDURE
Intervention: Total Mesorectal Excision
Description: Standard TME surgery openly or laporoscopically
Study NCT04405206 — intervention group
Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionnaires
Description: QLQ C30 and QLQ CR29
Study NCT00672048 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuing education
Description: Annual standard continuing education materials
Study NCT03895424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IFAC
Description: This intervention will contain the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope 58Fe
Study NCT03895424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MIFAC
Description: This intervention will contain the micellarized form of the iron fatty acid complex in a capsule. The complex will be labelled with the iron isotope with 57Fe
Study NCT03895424 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control Ferrous Sulfate
Description: This intervention will contain ferrous sulfate in the form of a solution labelled with the iron isotope 54Fe. A capsule with the same amount of fat as in the other arms will be administered to the participants
Study NCT03249922 — intervention group
Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
Study NCT02896660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraph Link
Description: Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
Study NCT02951663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Study NCT03574246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorhexidine gluconate %0,12 benzydamine hydrochloride %0,15
Description: chlorhexidine gluconate + benzydamine hydrochloride oral rinse
Study NCT03574246 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: %0.9 NaCl Solution
Description: isotonic sodium chloride
Study NCT01401920 — intervention group
Intervention type: OTHER
Intervention: leg elevation
Description: bilateral passive leg elevation for 30 seconds
Study NCT01401920 — intervention group
Intervention type: OTHER
Intervention: Trendelenburg position
Description: Trendelenburg position (15 degrees) for 30 seconds
Study NCT01401920 — intervention group
Intervention type: OTHER
Intervention: Trendelenburg position + passive leg elevation
Description: Trendelenburg position + passive leg elevation
Study NCT01401920 — intervention group
Intervention type: OTHER
Intervention: control group
Description: supine position without passive leg elevation or trendelenburg position
Study NCT00359229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Administration of Zolpidem 5mg
Study NCT03280537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Participants received omalizumab as a subcutaneous injection once every 2 weeks (q2w) or once every 4 weeks (q4w). The dose (from 75 mg up to 600 mg) and dosing frequency (q2w or q4w) was determined by serum total IgE level and body weight using the study-drug dosing table.
Study NCT03280537 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Study NCT05547815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 doses program
Description: Inoculate 5 doses of rabies vaccine, and collect blood at fixed time points to detect neutralizing antibody
Study NCT01860391 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diammine Silver Fluoride
Description: Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
Study NCT04676932 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Care Based on Kolcaba's Comfort Theory
Description: In this study, Nursing care based on Kolcaba's Comfort Theory will be applied for women undergoing HSG.
Study NCT03476356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral clomiphene citrate
Description: oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
Study NCT03476356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral clomiphene citrate
Description: oral clomiphene citrate 50 mg tablet, two times per day will be received from the third day of the cycle until the seventh day of the cycle.
Study NCT03476356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral carnitine supplementation
Description: oral carnitine supplementation 1g tablet, three times per day will be received from the third day of the cycle until the day of the pregnancy test.
Study NCT04200703 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult and Child Survivor Centered Approach
Description: Child welfare workers and supervisors, and community partners will be trained in the Adult and Child Survivor Centered Approach, and supervisors will receive ongoing coaching and training.
Study NCT03082456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular breast imaging
Description: Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 millicurie (mCi) Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
Study NCT03082456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Mammography
Description: During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
Study NCT03082456 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breast ultrasound
Description: Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
Study NCT03483181 — intervention group
Intervention type: DRUG
Intervention: Xarelto (rivaroxaban)
Description: An oral anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received rivaroxaban during one day prior to or two days after orthopedic surgery during the hospitalization.
Study NCT03483181 — intervention group
Intervention type: DRUG
Intervention: Lovenox (enoxaparin)
Description: An injectable anticoagulant medication for the prevention of VTE (Venous thromboembolism) related to orthopedic surgery. Patients received enoxaparin during one day prior to or two days after orthopedic surgeries during the hospitalization.
Study NCT01671384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate, Levocarnitine
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Study NCT01671384 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:~Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)~The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo.
Study NCT01875445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inositol
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Study NCT01875445 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
Study NCT04823000 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells (MSC)
Description: Repeated intrathecal and intravenous injection of autologous mesenchymal stem cells (1 million cells per Kg of body weight) at 6 months intervals.
Study NCT03306056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
Study NCT03306056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Strength Training
Description: Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 3 sets per exercise~* time-effort per session: \~90 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks
Study NCT03306056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-volume Strength Training
Description: Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:~* 5 strength training exercises (chest, upper/lower back, abdominals, legs)~* 1 set per exercise~* time-effort per session: \~20 min~* 2 training sessions per week~* duration of exercise intervention: 12 weeks
Study NCT03306056 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole-Body Electromyostimulation (WB-EMS)
Description: Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:~* time-effort per session: \~20 min~* duration of exercise intervention: 12 weeks
Study NCT04499456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalised Normative Feedback
Description: The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
Study NCT04499456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Personalised Normative Feedback
Description: The Personalised Normative Feedback provides information on 1) alcohol consumption (the number of drinks consumed, alcohol-pattern use, binge drinking); 2) normative comparisons; 3) alcohol-related consequences; 4) practical costs of alcohol consumption (money spent and calories consumed); 5) strategies to avoid or risks associated with alcohol use.
Study NCT01211574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer coach
Description: Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
Study NCT01211574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mentor
Description: Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
Study NCT01211574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Professional
Description: Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
Study NCT02853929 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
Study NCT02853929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
Study NCT00955747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagatose
Description: powder; 15 grams three times daily; one year
Study NCT00955747 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Substitute Splenda
Description: 1.5 g powder tid
Study NCT03286647 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral hygiene instruction
Description: the participants will receive instructions to perform a satisfatory oral hygiene
Study NCT03286647 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral hygiene instruction
Description: the participants will receive instructions to perform a satisfatory oral hygiene
Study NCT04465383 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqua© 30 on Oncomfort SedakitTM
Description: Digital Sedation session consists in a virtual reality software (Aqua© 30 Version 3.0, Oncomfort SA, Waver, Belgium) including a clinical hypnosis script.Patients in the intervention group will undergo a 30-minute Digital Sedation program through a VR headset and headphones. This medical device called Oncomfort SedakitTM has been created to reduce anxiety and pain during medical/ surgical interventions
Study NCT04465383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.
Study NCT01554462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid / Docosahexaenoic acid
Description: 650 mg EPA and 650 mg DHA daily
Study NCT01554462 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo dietary intervention (MUFA) in healthy control group
Description: Placebo contains MUFA in stead of PUFA, same energy value
Study NCT04571905 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Osteosynthesis with resorbable Material
Description: Osteosynthesis with Magnezix screws in fractures of the Epicondylus ulnaris and Condylus radialis under General anaesthesia
Study NCT04471688 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: infectious disease screening
Description: Explore the best detection strategy for patients with pre-transfusion/pre-operative infectious disease screening
Study NCT04465383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Standard sedation starting doses of 1 µg/ml to 6 µg/ml depending on patient's reaction and titrated incrementally by 0.5µg/ml. Doses are adapted according to the level of comfort and needs of the patient.